FDA Gives New Details on Faster Path for Personalized Gene Therapies
โฎ BeforePersonalized gene therapies have faced long approval routes designed for larger trials.
โ
NowThe FDA has published more detail on a quicker pathway for these treatments.
In short
- The FDA has released new details on an approval pathway for personalized gene therapies.
- The stated aim is to speed access to treatments for rare diseases.
- Rare disease advocates have welcomed the move, according to the source.
Why it's good news
Personalized gene therapies are built for very small groups of patients, so standard approval routes can be slow and costly. The FDA's new guidance sets out how a faster route might work. The source describes the move as welcomed by advocates, but does not say when or how the pathway will be used.
Advertisement
From STAT
Rare disease advocates applauded the FDA's move to speed access to treatments.
Ask this story
More like this
Advertisement